Protein therapeutics: A summary and pharmacological classification

被引：1569

作者：

Leader, Benjamin ^{[3
]}

Baca, Quentin J. ^{[1
,2
]}

Golan, David E. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, Dept Biochem & Mol Pharmacol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA

[3] Brown Med Sch, Dept Emergency Med, Providence, RI USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 01期

关键词：

D O I：

10.1038/nrd2399

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Once a rarely used subset of medical treatments, protein therapeutics have increased dramatically in number and frequency of use since the introduction of the first recombinant protein therapeutic-human insulin-25 years ago. Protein therapeutics already have a significant role in almost every field of medicine, but this role is still only in its infancy. This article overviews some of the key characteristics of protein therapeutics, summarizes the more than 130 protein therapeutics used currently and suggests a new classification of these proteins according to their pharmacological action.

引用

页码：21 / 39

页数：19

共 301 条

[1] TREATMENT OF HEMOPHILIA WITH GLYCINE-PRECIPITATED FACTOR 8 [J].

ABILDGAARD, CF ;

SIMONE, JV ;

CORRIGAN, JJ ;

SEELER, RA ;

EDELSTEIN, G ;

VANDERHEIDEN, J ;

SCHULMAN, I .

NEW ENGLAND JOURNAL OF MEDICINE, 1966, 275 (09) :471-+

[2] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections [J].

Abramson, JS ;

Baker, CJ ;

Baltimore, RS ;

Bocchini, JA ;

Long, SS ;

McMillan, JA ;

Meissner, HC ;

Powell, KR ;

Prober, CG ;

Rennels, MB ;

Saari, TN ;

Weiner, LB ;

Blackmon, L ;

Batton, DG ;

Bell, EF ;

Denson, SE ;

Engle, WA ;

Kanto, WP ;

Martin, GI ;

Stark, AR .

PEDIATRICS, 2003, 112 (06) :1447-1452

[3]

ALBERS CW, 2000, JAMA-J AM MED ASSOC, V283, P1145

[4] UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].

ALLAN, NC ;

RICHARDS, SM ;

SHEPHERD, PCA .

LANCET, 1995, 345 (8962) :1392-1397

[5] HYPOGLYCEMIA IN CHILDHOOD DIABETES .2. EFFECT OF SUBCUTANEOUS OR INTRAMUSCULAR INJECTION OF DIFFERENT DOSES OF GLUCAGON [J].

AMAN, J ;

WRANNE, L .

ACTA PAEDIATRICA SCANDINAVICA, 1988, 77 (04) :548-553

[6] MULTICENTER REPERFUSION TRIAL OF INTRAVENOUS ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX (APSAC) IN ACUTE MYOCARDIAL-INFARCTION - CONTROLLED COMPARISON WITH INTRACORONARY STREPTOKINASE [J].

ANDERSON, JL ;

ROTHBARD, RL ;

HACKWORTHY, RA ;

SORENSEN, SG ;

FITZPATRICK, PG ;

DAHL, CF ;

HAGAN, AD ;

BROWNE, KF ;

SYMKOVIAK, GP ;

MENLOVE, RL ;

BARRY, WH ;

ECKERSON, HW ;

MARDER, VJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (06) :1153-1163

[7] A RANDOMIZED TRIAL OF INTRACORONARY STREPTOKINASE IN THE TREATMENT OF ACUTE MYOCARDIAL-INFARCTION [J].

ANDERSON, JL ;

MARSHALL, HW ;

BRAY, BE ;

LUTZ, JR ;

FREDERICK, PR ;

YANOWITZ, FG ;

DATZ, FL ;

KLAUSNER, SC ;

HAGAN, AD .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (22) :1312-1318

[8]

[Anonymous], 1995, Lancet, V346, P329

[9]

[Anonymous], 2007, Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy

[10] Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].

Antman, EM ;

Giugliano, RP ;

Gibson, CM ;

McCabe, CH ;

Coussement, P ;

Kleiman, NS ;

Vahanian, A ;

Adgey, AAJ ;

Menown, I ;

Rupprecht, HJ ;

Van der Wieken, R ;

Ducas, J ;

Scherer, J ;

Anderson, K ;

Van de Werf, F ;

Braunwald, E .

CIRCULATION, 1999, 99 (21) :2720-2732

← 1 2 3 4 5 6 7 8 9 10 →